Difference in Tau levels in Alzheimer’s Disease according to sex and APOE-ε4 genotype

Takeaway

  • In Alzheimer’s Disease (AD), sex differences in cerebrospinal fluid (CSF) Tau and phosphorylated Tau (pTAU) are more evident in the early stages of disease among APOE-ε4 carriers, and the late stages of the disease in APOE-ε4 non-carriers.

Why this matters

  • Studies of pre-dementia subjects, but not post-mortem studies, indicate that females with the APOE-ε4 gene have higher CSF Tau and pTau compared with males carrying APOE-ε4.

  • A proper understanding of AD pathophysiology, including sex differences and pathophysiology timelines, could support appropriate treatment development.